Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Brewins £32m tech hit: what the analysts said

Brewins £32m tech hit: what the analysts said

Royal Bank of Canada was one of a series of brokers to maintain its outlook on Brewin Dolphin yesterday after the investment manager said it would write down £32 million in IT costs.  

RBC Capital Markets analyst Peter Lenardos pointed out that the pre-tax impairment charge would leave the capital position unchanged, ‘but the £32 million loss could be negative for sentiment’.

Shares in Brewin Dolphin ended yesterday 2.26% down at 320p. RBC has the company on an outperform rating with a price target of 327p. 

Canaccord Genuity reaffirmed its hold rating on the stock and its 304p price target. N1 Singer held the business at a buy with a 324p target, while Numis maintained its hold with a 350p target.

Analysts followed by Reuters rate the business a hold over a buy by a 2:1 margin, with a median current price target of 318p.  

An outstanding £15 million of charges remained to settled over the next 10 years, but Lenardos said in his view ‘the most likely outcome is the non-payment of the £15 million’.

He added that on the upside Brewin Dolphin’s profit margin before tax this year was likely to exceed the company’s target of 20%.

‘While £32 million and potentially £15 million more has been wasted, we would rather that the issue be identified and addressed now as opposed to at the project's conclusion,’ said Lenardos.  

‘We believe the phased-in approach allowed the company to test the system before a broader rollout occurred.

‘Since the company trades at 15.4 times 2015 earnings per share, a premium to the diversified financials sector at 13.5 times, we believe it faces a risk of derating. However, we emphasise that there is no impact on our financial forecasts… the business appears to be performing ahead of guidance and our forecasts.’


 

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Biotech Growth: we will ride out this storm

Biotech Growth: we will ride out this storm

Geoffrey Hsu of Biotech Growth Trust says the sell-off in biotechnology stocks represents a buying opportunity for long-term investors.

Play Sector Spotlight: Kleinwort Benson's Choukeir on UK equities

Sector Spotlight: Kleinwort Benson's Choukeir on UK equities

In our first Sector Spotlight of the year we explore UK equities on the back of the extreme market turbulence in 2016.

Play Picton: the UK property hotspots for rental income

Picton: the UK property hotspots for rental income

Picton Property Income CEO Michael Morris reveals how he is planning to ride the ‘ripple effect’ as UK economic growth spills out from the capital across the country.

Your Business: Cover Star Club

Profile: PortfolioMetrix is on a mission to kill 'Frankenstein' systems

Profile: PortfolioMetrix is on a mission to kill 'Frankenstein' systems

In a buyers’ market for off-the-peg discretionary management, self-funded start-ups begin at an inherent disadvantage

Wealth Manager on Twitter